Gout, not hyperuricemia alone, impairs left ventricular diastolic function by Jing-Chi Lin et al.
RESEARCH ARTICLE Open Access
Gout, not hyperuricemia alone, impairs left
ventricular diastolic function
Jing-Chi Lin1,4, Chun-Liang Lin3,4, Mien-Cheng Chen5, Pey-Jium Chang4, Shih-Tai Chang2, Chang-Min Chung2
and Kuo-Li Pan2,4*
Abstract
Introduction: Gout is a common metabolic disorder characterized by hyperuricemia and chronic inflammation.
Previous studies show that hyperuricemia accelerates the occurrence and worsening of cardiovascular disease due
to LV remodeling. However, it is still unclear whether hyperuricemia is the sole contributor to organic heart
remodeling in patients with gout. In addition, there is a paucity of data regarding the association between LV
diastolic function and gout. The objective of this study was to investigate the effects of gout on LV diastolic
function.
Methods: A total of 173 patients were divided into tertiles based on the following serum uric acid (UA) levels: 1)
serum UA ≤ 6.5 mg/dL (n = 54), 2) serum UA >6.5 to ≤8.5 mg/dL (n = 59), and 3) serum UA > 8.5 mg/dL
(n = 60).Patients underwent a comprehensive Doppler-echocardiography examination to evaluate LV volume,
systolic and diastolic function, and left atrial (LA) volume.
Results: LV diastolic parameters, including diastolic peak early transmitral flow velocity (E), late transmitral flow
velocity (A), E/A, peak early diastolic mitral annular velocity (Em), late diastolic annular velocity (Am), Em/Am, E/Em,
maximal LA volume index (LAVi) and prevalence of moderate to severe LV diastolic dysfunction were not
significantly different between the three groups. Among the population being studied, 108 individuals received a
gout diagnosis. Gout patients had greater LV end-systolic dimensions (27.08 ± 4.38 mm, p = 0.006), higher LV mass
index (107.18 ± 29.51 g/m2, p < 0.001), higher E/Em (10.07 ± 2.91, p = 0.008), and larger maximal LAVi (16.96 ±
7.39 mL/m2, p < 0.001) than patients without gout. The prevalence of moderate to severe LV diastolic dysfunction
was higher in patients with gout (23 %, p = 0.02).
Conclusions: Gout, not hyperuricemia alone, is associated with LV diastolic dysfunction and LA volume enlargement.
Keywords: Gout, Hyperuricemia, Diastolic dysfunction, Left atrial volume
Introduction
Gout is a common metabolic disorder characterized by
hyperuricemia and chronic inflammation [1]. Numerous
studies have reported elevated uric acid (UA) as a risk fac-
tor for coronary heart disease [2, 3], atrial fibrillation [4]
and cardiac mortality [5, 6]. In addition, hyperuricemia is
a demonstrated predictor of poor prognosis in various dis-
eases, including acute stroke, congestive heart failure,
acute ST-elevation myocardial infarction and chronic
renal disease [7–10]. Elevated UA is also associated with
left ventricular (LV) hypertrophy in patients without
underlying cardiovascular disease [11] and with diastolic
dysfunction in patients with heart failure [12]. Hyperurice-
mia accelerates the occurrence and worsening of cardio-
vascular disease due to LV remodeling.
In previous studies it has been observed that cardio-
vascular events are positively associated with gout. Early
evidence reported in the Framingham study found a
60 % increased risk of coronary artery disease (CAD)
among gout patients [13]. A Taiwanese study demon-
strated that the frequency of gout attacks was associated
with an odds ratio of 1.18 for myocardial infarction [14].
The MRFIT study found that gout was associated with a
26 % increased risk of acute myocardial infarction [15].
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Clinically, the severity of gout, rather than hyperurice-
mia, is more representative of the chronic inflammation
observed in gout patients. Epidemiologically, the study
of Kuo et al. demonstrated a link between gout, not hy-
peruricemia, and a higher risk of death from all causes
and cardiovascular diseases [6].
It is still unclear whether hyperuricemia is the sole
contributor to organic heart remodeling in patients with
gout. Furthermore, there is a paucity of data on the asso-
ciation between LV diastolic function and gout. There-
fore, the aim of the current study was to investigate the
effects of gout on LV diastolic function.
Methods
Subjects and study design
In this prospective study, patients without hyperuricemia,
with hyperuricemia, or with gouty arthritis, who under-
went echocardiographic examinations, were enrolled be-
tween October 2010 and February 2013. Initially, a total of
200 patients were enrolled in this study. Exclusion criteria
were the presence of moderate or severe valvular disease,
dilated or hypertrophic cardiomyopathy, LV systolic dys-
function (defined as LV ejection fraction (LVEF) <50 %),
left bundle branch block, second-degree or third-degree
atrioventricular conduction block, permanent cardiac
pacemaker implantation, atrial arrhythmias (such as atrial
fibrillation, atrial flutter, or atrial tachycardia documented
by electrocardiography), congenital heart disease, and a
history of previous cardiac surgery. Patients were also ex-
cluded if they had poor-qualitied echocardiographic im-
ages that precluded analysis.
This study was approved by Chang Gung Medical
Foundation Institutional Review Board (IRB 100-3022B)
and informed consent was obtained from all patients.
The clinical data recorded from the enrolled patients in-
cluded age, sex, height, weight, systolic blood pressure,
serum creatinine levels, serum UA levels, and absence or
presence of hypertension, diabetes mellitus, hypercholes-
terolemia, and smoking. Asymptomatic hyperuricemia
was defined as UA ≥7 mg/dL. The diagnosis of gouty
arthritis was made according to the American College of
Rheumatology (ACR)/Wallace criteria [16]. Patients who
had been diagnosed with gouty arthritis using ACR cri-
teria and received medication were also included in the
gouty arthritis group. Hypertension was defined as sys-
tolic blood pressure ≥140 mmHg and/or diastolic blood
pressure ≥90 mmHg. Additionally, patients who were re-
ceiving antihypertensive medication were also consid-
ered hypertensive. Diabetes mellitus was defined as a
fasting plasma glucose level ≥126 mg/dL. Patients re-
ceiving oral anti-glucose drugs or insulin for diabetes
mellitus control were also considered to have diabetes
mellitus. Hypercholesterolemia was defined as either the
use of cholesterol-lowering medication or having a total
serum cholesterol ≥250 mg/dL in the absence of
cholesterol-lowering medication.
Echocardiography
All subjects received transthoracic echocardiographic ex-
aminations at rest in the left lateral decubitus position
using a Philips iE33 ultrasound system and S5-1 broad-
band phased array transducer. The LA diameter in the
end-systolic phase, thickness of the interventricular
septum (IVS) and posterior wall (PW) in end-diastolic
phase, and LV end-diastolic and end-systolic dimensions
were all determined using the M-mode in the paraster-
nal long-axis view according to the recommendations of
the American Society of Echocardiography [6]. The left
ventricular ejection fraction (LVEF), which means LV
systolic function, was calculated using Simpson’s method
[6]. The LV mass was estimated by the Devereux for-
mula [17]. Then, the LV mass index was obtained as the
LV mass/body surface area (BSA). Mitral inflow veloci-
ties were evaluated with a 1- to 2-mm sample volume
placed at the mitral valve tip by pulse-wave tissue
Doppler imaging (TDI) in the apical four-chamber view.
Diastolic peak early (E) and late (A) transmitral flow vel-
ocity and the E to A ratio (E/A) were measured. In the
apical four-chamber view, the peak early diastolic mitral
annular velocity (Em) and peak late diastolic annular
velocity (Am) were obtained by pulse-wave TDI at the
septal site of the mitral annulus. The E/Em ratio was
used as an index of LV filling pressure [18]. LV end-
diastolic volume (LVEDV) and LV end-systolic volume
(LVESV) were measured in the apical four-chamber and
two-chamber views using the biplane modified Simp-
son’s method. Then, the LVEDV and LVESD indexes
were calculated as LVEDV/BSA and LVESV/BSA. Max-
imal left atrial volume (LAV) was also measured in the
apical four-chamber and two-chamber views using the
biplane modified Simpson’s method [19–21]. Maximal
LAV was measured just before mitral valve opening, and
the maximal LAVi was calculated as maximal LAV/BSA.
All echocardiographic parameters were measured from
an average of three beats. E/A and E/Em are the parame-
ters of LV diastolic dysfunction clinically. According to
the value of E/A and E/Em, moderate to severe LV dia-
stolic function was defined as (1) a pseudonormal pattern:
0.75 ≤ E/A ratio <1.5 and E/Em ratio >10 and (2) a re-
strictive pattern: E/A ratio ≥1.5 and E/Em ratio >10 [22].
Statistical analysis
Statistical analysis was performed using SPSS 18.0 statis-
tical software (SPSS Inc., Chicago, IL, USA). Continuous
data are presented as mean ± standard deviation (SD), and
dichotomous data as number and percentage. Compari-
sons of continuous variables between groups were per-
formed using analysis of variance (ANOVA) or the
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unpaired two-tailed t test. Categorical variables were com-
pared using the chi square (χ2) test. Multiple regression
analyses were performed to determine the associations
between gout and LV diastolic functional parameters, in-
cluding E/A, Em, Am, E/Em, and maximal LAV. The multi-
variate model was adjusted for age, sex, UA, creatinine,
diabetes mellitus, hypertension, hypercholesterolemia, and
smoking. Statistical significance was set at p <0.05. In 20
randomly selected subjects, the interobserver and intraob-
server variability in E/Em and maximal LAV measurements
were assessed by the coefficient of variation, where differ-
ences between measurements were expressed as the ratio
of the SD to the mean. Interobserver variability was
assessed by two independent observers and intraobserver
variability by one observer twice within a two-week period.
The interobserver variability of E/Em was 3.3 % and that of
maximal LAV was 2.2 %. The intraobserver variability of E/
Em was 1.8 % and that of maximal LAV was 1.5 %.
Results
Baseline characteristics of patients by UA tertile
A total of 27 patients were excluded because of the
presence of LV systolic dysfunction (n = 2), hypertrophic
cardiomyopathy (n = 2), permanent cardiac pacemaker
implantation (n = 2), atrial fibrillation (n = 2), and poor
echocardiographic images that precluded analysis (n = 19).
Thus, the final study population consisted of 173 patients,
who were divided into tertiles by serum level of UA as fol-
lows: group 1: serum UA ≤6.5 mg/dL (n = 54); group 2:
serum UA >6.5 to ≤8.5 mg/dL (n = 59); and group 3:
serum UA >8.5 mg/dL (n = 60).The mean UA levels of
these three groups were 5.03 ± 1.07, 7.63 ± 0.52, and
10.05 ± 1.17 mg/dL, respectively (p <0.001). The clinical
characteristics of the study population are listed in Table 1.
There were no significant differences between the three
groups in age, gender or creatinine levels, history of dia-
betes mellitus, hypertension or hypercholesterolemia, or
cigarette smoking. Among the echocardiographic parame-
ters, there were no significantly different LV volume
parameters between the three groups, including LV end-
diastolic dimensions, LV end-systolic dimensions, LVEDV,
LVEDV index, LVESV, LVESV index, and LV systolic func-
tion. However, patients grouped by tertiles of increasing
UA were significantly associated with a graded increase in
LV wall thickness, LV mass, and LV mass index. LV
diastolic parameters including E, A, E/A, Em, Am, Em/
Am, E/Em, maximal LAVi, and prevalence of moderate to
severe LV diastolic dysfunction were not significantly dif-
ferent between the three groups.
LV organic remodeling and diastolic dysfunction in
patients with gout
As there were no obvious findings in relation to uric-
acid-based grouping, we studied our patients according
to diagnosis of gouty arthritis, asymptomatic hyperurice-
mia and normo-uricemia. Among the study population,
108 individuals received a diagnosis of gout: 65 patients
(60 %) received uricostatic agents, 15 (14 %) received uri-
cosuric agents and 77 (71 %) received colchicines. Table 1
shows the baseline characteristics of individuals with and
without gout. There were no significant differences in age
or gender, history of diabetes mellitus, hypertension or
hypercholesterolemia, or cigarette smoking between the
patients with and without gout. The patients with gout
had significantly higher serum UA levels than those with-
out gout (8.19 ± 2.04 mg/dL, p <0.001). Furthermore,
patients with gout had significantly worse renal function
than those without gout (creatinine 1.34 ± 1.09 mg/dL,
p <0.001 and estimated glomerular filtration rate (eGFR)
75.05 ± 34.2 ml/min, p = 0.059).
The echocardiographic parameters of patients with and
without gout are summarized in Table 1. Patients with
gout had a significantly thicker IVS (10.49 ± 1.66 mm, p =
0.004) and PW than those without gout (10.93 ± 1.64 mm,
p = 0.006). The LV mass was significantly larger in patients
with gout than in those without (193.90 ± 52.59 vs.
164.54 ± 47.97 g/m2, p <0.001). The LV mass index in the
patients with gout was also significantly higher than in
those without gout (107.18 ± 29.51 vs. 95.4 ± 26.57 g/m2,
p = 0.009). Additionally, patients with gout had greater LV
end-diastolic dimensions (LVEDd) than patients without
gout (48.27 ± 5.53 vs 46.36 ± 5.52 mm, p = 0.031). There
were no significant differences in LV end-systolic dimen-
sions (LVESd), LVEDV index, and LVESV index between
the patients with and without gout. Additionally, there
were no significant differences in LV systolic function be-
tween patients with and without gout. Among the LV dia-
stolic functional parameters, the E, A, and E/A ratio were
not significantly different between patients with and with-
out gout. The patients with gout had significantly lower
Em than those without gout (7.03 ± 2.02 vs. 8.45 ± 2.7,
p = 0.001). The Am was not significantly different be-
tween groups. The Em/Am ratio was lower in patients
with gout (0.82 ± 0.31, p <0.001), and the E/Em ratio
was higher in the patients with gout (10.07 ± 2.91, p =
0.008). Furthermore, the maximal LAVi of the patients
with gout was significantly larger than that of the pa-
tients without gout (16.96 ± 7.39 mL/m2, p <0.001).
Finally, the prevalence of moderate to severe LV dia-
stolic dysfunction was higher in patients with gout
than in patients without gout (23 % vs. 8 %, p = 0.016).
There were significant differences between the normo-
uricemia and hyperuricemia group, in uric acid, creatinine
(0.83 ± 0.19 vs. 1.01 ± 0.13 mg/dL, p <0.001), IVS (9.37 ±
1.61 vs. 10.27 ± 1.85 mm, p = 0.41) and LV mass (154.11 ±
48.92 vs. 177.80 ± 41.77 g/m, p = 0.42). There were no fur-
ther statistically significant differences between the normo-
uricemia and hyperuricemia groups (data not shown).
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Table 1 Baseline characteristics of patients grouped by tertiles of serum uric acid and gout
Variables First (<6.5 mg/dL)
(n = 54)
Second (>6.5 and







Gout (n = 108) P value Non-gout
(n = 65)
P value
Age (years) 56.86 ± 15.36 55.79 ± 11.68 58.44 ± 13.38 0.56 53.54 ± 15.64 56.96 ± 16.07 58.20 ± 11.76 0.20 55.09 ± 16.17 0.154
Men 42 (78 %) 54 (92 %) 54 (90 %) 0.064 26 (74 %) 27 (90 %) 97 (90 %) 0.06 50 (81 %) 0.079
Body surface area (m2) 1.70 ± 0.20 1.83 ± 0.22* 1.81 ± 0.18* 0.002 1.68 ± 0.19 1.77 ± 0.16 1.82 ± 0.20* 0.003 1.72 ± 0.18* 0.004
Uric acid (mg/dL) 5.03 ± 1.07 7.63 ± 0.52* 10.05 ± 1.17*† <0.001 4.96 ± 1.04 8.87 ± 1.42* 8.19 ± 2.04* <0.001 6.68 ± 2.3** <0.001
Creatinine (mg/dL) 1.0 ± 0.43 1.19 ± 0.38 1.34 ± 1.4 0.115 0.83 ± 0.19 1.01 ± 0.13 1.34 ± 1.09* 0.006 0.9 ± 0.19** <0.001
eGFR 81.68 ± 32.80 81.33 ± 34.91 74.53 ± 31.12 0.41 90.14 ± 30.08 80.67 ± 29.21 75.05 ± 34.20 0.059 85.77 ± 29.83** 0.038
Diabetes mellitus 3 (6 %) 2 (3 %) 6 (10 %) 0.322 2 (6 %) 3 (10 %) 6 (6 %) 0.60 5 (8 %) 0.492
Hypertension 11 (20 %) 12 (20 %) 15 (25 %) 0.781 8 (23 %) 8 (27 %) 22 (20 %) 0.78 16 (26 %) 0.362
Hypercholesterolemia 14 (26 %) 20 (34 %) 19 (32 %) 0.641 17 (49 %) 13 (43 %) 45 (42 %) 0.79 17 (27 %) 0.493
Smoking 6 (11 %) 13 (22 %) 6 (10 %) 0.123 5 (14 %) 5 (17 %) 15 (14 %) 0.95 10 (16 %) 0.657
LV dimensions and volume
IVS (mm) 9.51 ± 1.32 10.65 ± 1.8* 10.45 ± 1.82* 0.001 9.37 ± 1.61 10.27 ± 1.85 10.49 ± 1.66* 0.004 9.79 ± 1.81** 0.017
LVEDd (mm) 46.76 ± 5.94 48.12 ± 4.97 47.79 ± 5.72 0.404 45.80 ± 6.11 47.15 ± 4.47 48.27 ± 5.53 0.06 46.36 ± 5.52** 0.031
PW (mm) 9.85 ± 1.35 11.15 ± 1.52* 10.94 ± 1.86* <0.001 9.89 ± 1.56 10.64 ± 1.71 10.93 ± 1.64* 0.006 10.21 ± 1.66** 0.007
LVESd (mm) 26.37 ± 4.55 27.05 ± 4.29 27.04 ± 4.36 0.643 25.64 ± 4.77 27.31 ± 3.77 27.08 ± 4.38 '0.19 26.32 ± 4.43 0.255
LV mass (g/m) 159.6 ± 44.48 195.18 ± 48.37* 192.24 ± 56.28* <0.001 154.11 ± 48.92 177.80 ± 41.77 193.90 ± 52.59 * < 0.001 164.54 ± 47.97** <0.001
LV mass index (g/m2) 93.78 ± 25.09 107.57 ± 28.39* 106.2 ± 30.61* 0.019 91.14 ± 27.03 100.56 ± 24.09 107.18 ± 29.51 *0.01 95.4 ± 26.57** 0.009
LVEDV (mL) 69.33 ± 19.61 77.29 ± 20.37 72.75 ± 20.21 0.11 66.97 ± 20.19 68.80 ± 19.80 76.49 ± 19.81* 0.02 67.73 ± 20.36** 0.008
LVEDV index (mL/m2) 40.83 ± 11.46 42.29 ± 10.81 40.11 ± 10.29 0.538 39.55 ± 10.33 38.51 ± 9.87 42.28 ± 11.12 0.15 39.09 ± 10.3 0.066
LVESV (mL) 19.59 ± 8.14 22.12 ± 8.55 20.07 ± 7.48 0.205 18.54 ± 7.28 19.67 ± 9.25 21.56 ± 7.91 0.12 19.26 ± 8.35 0.105
LVESV index (mL/m2) 11.62 ± 5.19 12.1 ± 4.76 11.07 ± 4.03 0.404 10.96 ± 3.91 10.93 ± 4.84 11.98 ± 4.82 0.37 11.08 ± 4.4 0.265
LV systolic function
LVEF (%) 73.99 ± 9.2 74.28 ± 7.22 73.82 ± 7.26 0.95 72.57 ± 5.42 72.50 ± 6.98 71.95 ± 6.08 0.83 73.67 ± 8.84 0.671
LV diastolic function
E (m/s) 0.71 ± 0.15 0.66 ± 0.13 0.67 ± 0.17 0.117 0.78 ± 0.15 0.65 ± 0.14 0.67 ± 0.15 0.31 0.69 ± 0.15 0.475
A (m/s) 0.74 ± 0.2 0.73 ± 0.2 0.75 ± 0.19 0.872 0.71 ± 0.17 0.75 ± 0.22 0.74 ± 0.19 0.74 0.74 ± 0.2 0.853
E/A 1.03 ± 0.35 0.99 ± 0.36 0.95 ± 0.34 0.514 1.05 ± 0.38 0.92 ± 0.30 0.98 ± 0.34 0.32 0.99 ± 0.36 0.895
Em (cm/s) 8.12 ± 2.82 7.34 ± 2.22 7.24 ± 2.04 0.102 8.79 ± 3.04 7.94 ± 2.15 7.03 ± 2.02* <0.001 8.45 ± 2.7** 0.001
Am (cm/s) 8.42 ± 1.57 8.93 ± 1.74 9.14 ± 2.2 0.117 8.24 ± 1.54 9.01 ± 2.14 8.98 ± 1.87 0.11 8.69 ± 1.88 0.414













Table 1 Baseline characteristics of patients grouped by tertiles of serum uric acid and gout (Continued)
E/Em 9.49 ± 3.05 9.47 ± 2.48 9.67 ± 3.12 0.918 8.58 ± 2.07 8.79 ± 3.31 10.07 ± 2.91* 0.008 8.72 ± 2.74** 0.004
Maximal LAVi (mL/m2) 12.94 ± 5.80 16.45 ± 6.59* 15.77 ± 7.18 0.013 11.49 ± 3.36 12.71 ± 4.20 16.96 ± 7.39*f <0.001 20.34 ± 4.86** <0.001
Moderate-to-severe LV diastolic
dysfunction
7 (13 %) 9 (15 %) 14 (23 %) 0.301 2 (6 %) 3 (10 %) 25 (23 %) 0.02 5(8 %)** 0.016
Data are expressed as mean ± standard deviation or number (percentage). *P <0.05 versus group with uric acid (UA) ≤6.5 mg/dL group or normo-uricemic group. **P <0.05 compared with gout group. †P <0.05 versus group
with UA >6.5 and ≤8.5 mg/Dl or the hyperuricemic group. Moderate-to-severe LV diastolic dysfunction: (1) pseudonormal pattern: 0.75 ≤ E/A ratio <1.5 and E/Em ratio >10 and (2) restrictive pattern: E/A ratio ≥1.5 and E/Em
ratio >10. eGFR estimated glomerular filtration rate, A late diastolic peak transmitral flow velocity, Am peak late diastolic annular velocity, E early diastolic peak transmitral flow velocity, Em peak early diastolic mitral annular
velocity, IVS interventricular septum, LAVi left atrial volume index, LV left ventricle, LVEDd LV end-diastolic diameter, LVEDV LV end-diastolic volume, LVEF LV ejection fraction, LVESd LV end-systolic diameter, LVESV LV













On multivariate analysis, the associations between
gout and LV diastolic functional parameters, including
Em, Am, Em/Am, E/Em and maximal LAVi, were sig-
nificant when controlled for age, sex, UA, creatinine,
diabetes mellitus, hypertension, hypercholesterolemia
and smoking in the study groups (Table 2).
Discussion
The major finding of this study was that gout impacts LV
diastolic dysfunction and LA volume enlargement. LV dia-
stolic remodeling may be a predictor of adverse cardiac
events in gout patients. LV diastolic dysfunction refers to an
abnormality of diastolic distensibility, filling, or relaxation of
the LV [23]. LV diastolic dysfunction has major effects on
the LA, which is a transporting chamber that receives blood
from the pulmonary veins and conveys it to the LV through
both passive and active diastolic filling [24, 25]. Echocardio-
graphic evidence of diastolic dysfunction is an independent
risk factor for heart failure [26]. LV diastolic dysfunction in-
creases atrial afterload, atrial stretch, and atrial wall stress as
a result of dilation, which can promote atrial fibrillation. In
the study of Tsang et al., more severe diastolic dysfunction
and increased LAVi were associated with an increased risk
of incident atrial fibrillation [27]. In addition, diabetes melli-
tus patients with moderate to severe diastolic dysfunction
have an increased risk of incident atrial fibrillation [28]. The
severity of LV diastolic dysfunction and LA enlargement
can predict cardiovascular events.
Elevated serum UA levels are associated with diastolic
dysfunction in chronic heart failure patients with LVEF
<45 %, due to free radical-mediated endothelial damage
resulting from increased xanthine oxidase activity [12].
High UA levels were associated with increased LV mass,
end-diastolic LV dimensions, and IVS thickness com-
pared with patients with low UA levels in the present
study (Table 1) and that of Krishnan et al. [29]. A pos-
sible mechanism to explain this observed relationship is
the accumulation of reactive oxygen species due to up-
regulation of xanthine oxidase in hyperuricemia.
Gout is a metabolic disorder characterized by hyper-
uricemia and a type of chronic inflammatory arthritis in-
duced by deposition of monosodium urate crystals in
the synovial fluid and other tissues [1]. Accumulating
evidence from previous studies supports the existence of
a repetitive and progressive state of inflammatory activa-
tion that is strongly associated with the progression of
ventricular diastolic dysfunction and characterized by
the intense release and activation of circulating cytokines
[30, 31]. Whether hyperuricemia alone contributes to LV
organic and functional remodeling in gout patients re-
mains contentious. The current study is the first to
evaluate LV diastolic function in gout patients and to de-
termine the role of chronic gout-related inflammation in
LV diastolic dysfunction remodeling. In the present
study, LV diastolic functional parameters, including E/A,
Em, Am, E/Em, and maximal LAVi, were not signifi-
cantly different between the groups with low and high
serum UA. Furthermore, there was no association be-
tween serum UA and moderate-to-severe LV diastolic
dysfunction (Table 1).
Interestingly, lower Em and higher E/Em were detected
in patients with gout than in those without gout, and the
prevalence of moderate-to-severe LV diastolic dysfunction
was higher in patients with gout than those without gout
(23 %, vs. 8 %, p = 0.016; Table 1); however, there was no
difference between those with normo-uricemia and hyper-
uricemia. E/Em is an excellent predictor of LV filling pres-
sure and a parameter of LV diastolic function [32, 33]. A
possible explanation for these observations is that patients
with gout present with monosodium urate crystal-
mediated inflammatory cytokines including tumor necro-
sis factor-α (TNF-α) and interleukin-1β (IL-1β), which
have been implicated in the pathogenesis of myocardial
dysfunction [34]. Maximal LAVi was also larger in pa-
tients with gout than those without gout and there was no
difference between the normo-uricemia and hyperurice-
mia group. LA enlargement is primarily the result of pres-
sure or volume overload, and can serve as an index of
atrial remodeling [35]. In our study gout was an independ-
ent factor of impaired LV diastolic dysfunction, including
decreased Em, decreased Em/Am, and increased E/Em
(Table 2). Maximal LAVi was negatively associated with
Em (r = −0.225, p = 0.018) and positively associated with
E/Em (r = 0.343, p <0.001) (Fig. 1). Gout impairs LV
Table 2 Multivariate regression analysis of the association
between left ventricular diastolic functional parameters and the
gout study groups (n = 173)
Variable Unadjusteda Model 1b
ß P ß p
E/A
Gout −0.01 0.894 0.077 0.237
Em (cm/s)
Gout −0.282 <0.001 −0.208 0.002
Am (cm/s)
Gout 0.062 0.414 −0.019 0.815
Em/Am
Gout −0.257 0.001 −0.163 0.016
E/Em
Gout 0.214 0.005 0.172 0.02
Maximal LAVi (mL/m2)
Gout 0.35 <0.001 0.294 <0.001
aIncluding gout. bAdjusted for age, sex, uric acid, creatinine, diabetes mellitus,
hypertension, hyperlipidemia, and smoking. A late diastolic peak transmitral
flow velocity, Am peak late diastolic annular velocity, E early diastolic peak
transmitral flow velocity, Em peak early diastolic mitral annular velocity, LAVi
left atrial volume index
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compliance, which increases LV filling pressure. During
ventricular diastole, the LA is directly exposed to LV pres-
sure through the open mitral valve. Consequently, LA
pressure increases in order to maintain adequate LV fill-
ing, which results in increased LA wall tension and ultim-
ately LA enlargement. Therefore, enlarged LA volume
may reflect the severity of diastolic dysfunction in gouty
arthritis patients. These results suggest that in patients
with gout, LV diastolic remodeling might be associated
with the inflammation mediated by monosodium urate
crystals rather than isolated hyperuricemia.
There are several limitations in the present study.
First, further follow-up cohort studies are necessary to
demonstrate whether LV diastolic remodeling is predict-
ive of adverse cardiac events in patients with gout.
Second, the biological link between gout and LV dia-
stolic dysfunction remains unclear; our current hypoth-
eses and results require further clarification through
additional studies.
Conclusion
Gout, rather than hyperuricemia, is associated with LV
diastolic dysfunction and LA volume enlargement. LV
diastolic remodeling may be a predictor of adverse
cardiac events in patients with gout.
Abbreviations
BSA: body surface area; IVS: interventricular septum; LV: left ventricular;
LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume;
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